Tissue attachment devices and methods for prosthetic heart valves

Information

  • Patent Grant
  • 8696743
  • Patent Number
    8,696,743
  • Date Filed
    Thursday, April 16, 2009
    15 years ago
  • Date Issued
    Tuesday, April 15, 2014
    10 years ago
Abstract
A multi-leaflet valve, which includes at least two leaflets, an outer tube, and a seam protector for each seam. Each seam protector is positioned to be in contact with a portion of the outer tube, with tube portions and leaflet ends being positioned between adjacent seam protection pieces. The seam protectors provide a lower stress surface about which the leaflets can bend or flex during their opening and closing. The seam protectors may include an enlarged end portion with an extending straight surface, an inverted U-shaped structure, or a sinusoidal-shaped structure, for example. The valve can further be provided with a seam cover or protector that is stitched onto the seam allowance of the layers of one or more of the seams. The seams can be provided with one or more inserts to fill spaces between adjacent tissue layers and create tension in certain material sheets.
Description
TECHNICAL FIELD

The present invention relates generally to treatment of cardiac heart disease. More particularly, the present invention relates to implantable valve prostheses for implantation into the cardiac system.


BACKGROUND

All four of the valves in the heart are passive structures in that they do not themselves expend any energy and do not perform any active contractile function. They consist of moveable “leaflets” that open and close in response to differential pressures on either side of the valve. The problems that can develop with valves can generally be classified into two categories: (1) stenosis, in which a valve does not open properly, and (2) insufficiency (also called regurgitation), in which a valve does not close properly. Stenosis and insufficiency may occur concomitantly in the same valve or in different valves. Both of these abnormalities increase the workload placed on the heart. The severity of this increased stress on the heart and the patient, and the heart's ability to adapt to it, determine the treatment options that can be pursued. In some cases, medication can be sufficient to treat the patient, which is the preferred alternative; however, in many cases defective valves have to be repaired or completely replaced in order for the patient to live a normal life.


The two general categories of valves that are available for implantation into the cardiac system are mechanical valves and bioprosthetic or tissue valves. Mechanical valves have been used for many years and encompass a wide variety of designs that accommodate the blood flow requirements of the particular location where they will be implanted. Although the materials and design features of these valves are continuously being improved, they do increase the risk of clotting in the blood stream, which can lead to a heart attack or stroke. Thus, mechanical valve recipients must take anti-coagulant drugs for life to lessen the potential for blood clot formation. Further, mechanical valves can sometimes suffer from structural problems that may force the patient to have additional surgeries for further valve replacement.


Bioprosthetic valves, which are also referred to as prosthetic valves, generally include both human tissue valves and animal tissue valves. The designs of these bioprosthetic valves are typically relatively similar to the design of the natural valves of the patient and advantageously do not require the use of long-term anti-coagulant drugs. Human tissue valves are typically not available in large quantities, however, since they must be removed from deceased persons who have elected organ donation. On the other hand, due to the large numbers of animals routinely processed at meat processing facilities, for example, animal tissue valves are more widely available for the patients who require valve replacement. The most common types of animal tissue valves used include porcine aortic valves, and bovine and porcine pericardial valves, some of which are incorporated with some type of a stent before implantation in a patient. In the case of pericardial valves, the use of pericardial material to design and make the heart valves provides a much larger range of design options than is available when using only harvested valves.


In order to incorporate a tissue valve with a stent or other type of frame, a number of different techniques and methods have been used, such as clamping, tying, gluing, or stitching, for example. However, many of the techniques used for this purpose generally produce a stented valve that has concentrated stresses at the points where the leaflets are attached to the stent frame. That is, because the stents are relatively rigid as compared to the flexible material from which the leaflets of the tissue valve are made, the repetitive flexing motion of the leaflets can create stress concentrations at the points where the tissue valve is attached to the stent. These stress concentrations can eventually lead to tearing of the tissue, valve leakage, and/or failure of the heart valve. The attachment points can also be sites for abrasion of the tissue that can lead to tearing of the tissue. Thus, there is a continued need to be able to provide methods and devices for a durable attachment between a tissue valve and a stent and/or to distribute the stresses away from the attachment and seam areas and provide for nonabrasive contact surfaces for bioprosthetic heart valve leaflets.


SUMMARY

The present invention is directed to a prosthetic cardiac valve and methods of making such a valve. In particular, embodiments of the invention are directed to protection of seams that are formed by the attachment of pieces of tissue material when making a tubular valve.


In one aspect of the invention a multi-leaflet valve is provided, which includes at least two leaflets made from pericardial material, for example, an outer tube, and a seam protector for each seam. Each seam protector is positioned to be in contact with a portion of the outer tube, with tube portions and leaflet ends being positioned between adjacent seam protection pieces. The seam protectors provide a lower stress surface about which the leaflets can bend or flex during their opening and closing. The seam protectors may be configured in a number of different ways, including an enlarged end portion with an extending straight surface, an inverted U-shaped structure, a sinusoidal-shaped structure, and the like. The valve can further be provided with a seam cover or protector that is stitched onto the seam allowance of the layers of one or more of the seams. The seams can be provided with one or more inserts to fill spaces between adjacent tissue layers and create tension in certain material sheets, thereby providing a relatively soft hinging surface for the leaflets.


In one aspect of the invention, seam protection is provided by configuring a free end of tube material into a roll or coil at the seam area. In another aspect of the invention, a strip of material can be provided for seam support and to provide an element about which leaflets can bend.


In another aspect of the invention, a sheet of pericardium material can be cut or otherwise made into a disc of material from which a hole is cut in its central area. The inner hole can be attached to a stent frame and a plate or other fixture can be used to form the leaflet shapes.





BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be further explained with reference to the appended Figures, wherein like structure is referred to by like numerals throughout the several views, and wherein:



FIG. 1 is a schematic perspective view of a pericardial tri-leaflet valve of the invention;



FIG. 2 is a cross-sectional top view of one seam of the pericardial valve of FIG. 1, including one aspect of a seam protection configuration;



FIG. 3 is a perspective view of the seam of FIG. 2;



FIG. 4 is an isometric view of a seam protection fixture of the type used in FIGS. 1-3;



FIG. 5 is a perspective view of another seam protection configuration adjacent to a seam of a pericardial valve;



FIGS. 6-8 are cross-sectional views of different seam protection features attached to seams of a valve;



FIG. 9 is a perspective view of a seam protection feature with a seam of a valve;



FIG. 10 is a cross-sectional side view of a seam protection feature incorporating a fabric coated with silicone and cured into a sinusoidal shape;



FIGS. 11-12 are perspective views of seam protection features attached to a seam of a valve;



FIG. 13 is a schematic view of a seam attachment configuration for a valve of the invention;



FIGS. 14 and 15 are perspective views of additional seam protection embodiments of a valve;



FIG. 16 is a cross-sectional view of a seam including an attached seam protector;



FIGS. 17
a through 21b are schematic top views of seam protectors in pairs, where each pair of Figures includes the seam protector in its operational position and a mold configuration for making that seam protector;



FIG. 22 is a perspective view of a seam construction that includes the use of a back plate and support structures;



FIG. 23 is a front view of material used in forming a leaflet and including two support inserts;



FIGS. 24-29 are schematic side views of seam configurations of valves that are constructed with at least one element in addition to the tissue layers about which leaflets of the valve can flex;



FIGS. 30 and 31 are perspective views of additional tissue seam constructions;



FIG. 32 is a schematic top view of a seam configuration that includes non-circular structures stitched into the seam;



FIG. 33 is a schematic top view of a seam configuration that includes a sewing strip;



FIGS. 34 and 35 are front views of exemplary sewing strips that can be used in seam constructions for valves, and



FIG. 36 is a perspective view of a shortened sewing strip of FIG. 35;



FIGS. 37-42 are cross-sectional side and perspective views of attachment configurations between leaflets and an outer tube, along with structures that are positioned to change stresses in the leaflet flexing areas;



FIG. 43 is a schematic top view of a stented valve configuration including an additional cloth area in the construction;



FIG. 44 is a top schematic view of a circular shaped disc of pericardial material that will be used in creating a valve;



FIG. 45 is a schematic top view of the disc of FIG. 44 after a fixture has been used to form leaflet shapes from the pericardial material; and



FIGS. 46 and 47 are top views of a seam protection feature provided by the material that forms the leaflet and the valve wall.





DETAILED DESCRIPTION

Pericardial valves of the invention can be used for replacement of pulmonary valves, aortic valves, mitral valves, or tricuspid valves, in accordance with the methods and valve constructions of the invention described herein. Alternatively, the valves of the invention can be used to replace a failed bioprosthesis, such as in the area of an aortic valve or mitral valve, for example. The shape, size, and configuration of the outer tubular portion of the pericardial valve can specifically be designed and chosen for the type of valve that is being produced. The valves of the invention can include stented or stentless valves, but in either case, the valves are preferably compressible to a reduced diameter during the implantation process, such as for transcatheter implantation, and can be capable of being expanded to a larger diameter once they are in their desired implantation location. The valve assemblies can be used as a surgical sutureless or apical implant, and can be utilized in percutaneous replacement of cardiac valves, for example. One exemplary method for assembling a stented valve of the invention generally includes the manufacture and preparation of a valve segment, then a subsequent mounting or attachment of the prepared valve segment to a stent, which is described in further detail below.


Referring now to the Figures, wherein the components are labeled with like numerals throughout the several Figures, and initially to FIG. 1, a standard pericardial valve assembly 10 is illustrated, with its seams being located generally at the intersection line of adjacent leaflets. For the valve assembly 10, along with various embodiments of the invention described herein, at least one relatively flat sheet of pericardium material is used in their construction, which may be obtained, for example, from a swine. It is understood that other donor species may alternatively be used, or that the material used is not a pericardium material but instead is a different type of tissue or material, such as a polymer or bio-engineered film. The pericardium material may be at least partially fixed or cross-linked with a buffered gluteraldehyde solution or other solution at some point during the assembly process, in order to make the material easier for an operator to handle and manipulate. In one specific example, a piece of porcine pericardium is obtained, which is rinsed for approximately 10 minutes in a buffered gluteraldehyde solution to partially cross-link the material. U.S. Pat. No. 4,976,733 (Girardot), titled “Prevention of Prosthesis Calcification”, describes a variety of additional exemplary methods of treating pericardium material that may be useful with the systems and methods of the present invention, along with methods for retarding or preventing the calcification of a prosthesis implanted in a mammal. However, such treatments to the material are optional and may be different depending on operator preference, the material chosen, and the like.


The piece of pericardium can then be cut to a predetermined shape and size to make the valve walls and leaflets of the valve assemblies of the invention, as will be described in detail relative to a number of embodiments of the invention. If the material is thicker than desired, the thickness can be reduced using a number of methods for effectively removing some of the thickness of the pericardium material without sacrificing an undesirable amount of the strength of the material.


Referring to FIGS. 2-4, a seam of a valve is shown, which can be part of a bi-leaflet or tri-leaflet valve including two or three seams, respectively, attaching adjacent leaflets to each other and to an outside tube. The illustrated seam includes an end portion of a first leaflet 12, an end portion of a second leaflet 14, a first outer tube portion 16 that is adjacent to the first leaflet 12, and a second outer tube portion 18 that is adjacent to the second leaflet 14. As shown, the leaflets 12, 14 are positioned adjacent to each other and in between tube portions 16, 18 to create a stacked configuration at the seam. It is noted that the opposite sides or ends of each of the leaflet pieces would be attached at seams that are spaced from each other in order to create a multi-leaflet structure.


The seam protector comprises a first side piece 20 positioned to be in contact with the first outer tube portion 16 and a second side piece 22 (which is optionally configured to mirror the first side piece 20) positioned to be in contact with the second outer tube portion 18. The side pieces 20, 22 may be molded out of silicone, reinforced silicone, or plastic, for example, and are at least slightly more rigid than the leaflet and outer tube materials of the valve. As shown, each of the side pieces 20, 22 includes an enlarged end portion 26 from which a straight or flat portion 28 extends. The relative sizes and shapes shown for the enlarged end 26 and straight portions 28 of the side pieces 20, 22 are exemplary and can be different from that shown in the figures. In any case, the enlarged end portion 26 of each of the side pieces 20, 22 can be relatively cylindrical in shape and can provide a relatively gentle transition area for the outer tube portions. In this way, the stress concentrations in this area can be reduced. In addition, the enlarged end portion 26 provides a smooth surface to minimize abrasion where the leaflets open and close. Further, side pieces 28 can include multiple sewing holes 24, as shown in FIG. 4. Because these sewing holes 24 provide the locations through which sutures or other material can be inserted for attaching the layers of material to each other and to the side pieces 20, 22 of the seam protector, the positioning of these holes 24 (e.g., their distance from the enlarged end portion 26) can advantageously determine how far the stitching is spaced from the area about which the leaflets open and close. For example, in order to move the sewing line of the seam farther from the outer tubular wall of the valve assembly, the distance from the sewing holes 24 to the enlarged end portion of each side piece can be increased.


In order to assemble pericardial pieces at each of the seams of a tri-leaflet valve, three pieces of tissue are provided for the leaflets, each of which will be stitched outside of the stitch line that would normally be used. This stitching will position the seams away from the point or line along which the leaflets open and close. It is also contemplated to tack certain pieces of the pericardium that will be part of the structure to portions of a seam protector prior to placing all of the pieces in contact with each other. It is further contemplated that a clamp can be used to hold the pieces together during and/or after the stitching is complete.


Three similar or identical seam arrangements can be used to form a tubular structure of the type referred to as a tri-leaflet valve, or the seams can be configured differently from each other. In any case, seam protectors are preferably provided at each of the three seam areas. The valve assembly can then be attached to a compressible stent or other compressible structure for percutaneous or surgical delivery to the heart of a patient, for example.



FIG. 5 illustrates another embodiment of a seam protector 30, which includes a first side piece 32 and a second side piece 34. Seam protector 30 also includes multiple sewing holes 36 that can again be spaced at a distance from the area about which the leaflets open and close in order to provide a stitch line that is not located at the area of the highest stress concentration for the leaflets. Side pieces 32, 34 have a generally rectangular shape with a curved distal edge 38 that is positioned against the outer layer of the tubular structure of the valve. As with other seam protectors described and shown herein, the curved or rounded edges 38 are intended to create a smooth transitional region around which tissue can bend, which is located at some distance from the seam in order to prevent tearing at the stitch line.



FIG. 6 illustrates another seam protection embodiment of the invention, which is used at a seam of a valve where first and second leaflets 50, 52 are attached to outer tube portions 54, 56 in a manner similar to that described above. This area further includes a seam protector 60 that is shown as having an inverted U-shaped portion 62 that covers the raw edges of the leaflets 50, 52 and tube portions 54, 56. The seam protector 60 further includes U-shaped portions 64, 66 that extend from opposite ends of the inverted U-shaped portion 62. All of these layers of material can then be stitched to each other, in a location that is spaced from the outer tubular wall, such as is shown by stitch 70. The bottom of the U-shaped portions 64, 66 are spaced from the stitch line and positioned to provide a curved surface around which the tissue can bend. The seam protector 60 can be a single or multiple layer structure. For one exemplary embodiment of a dual layer structure, a first layer 72 can be Dacron, fabric, or a silicone adhesive layer, and a second layer 74 can be a tissue material, such as a pericardial tissue, although a wide variety of biocompatible materials can be used. The layers 72, 74 can be attached to each other in a variety of ways, such as by sewing, ultrasonically welding, laser welding, or adhering the layers to each other with tissue glue. The first layer 72 can be provided with a large enough thickness so that the rounded edges created at the bottom of the portions 64, 66 provide a sufficiently large radius about which the tissue can bend.



FIG. 7 is another exemplary seam protection embodiment that is similar to that shown in FIG. 6; however, a seam protector 80 of FIG. 7 further includes a structure or member 82 positioned within the open area of one or both of its U-shaped portions 86. The structure 82 provides additional structural integrity to the area about which the tissue can bend. The structure 82 may be made of a wide variety of materials, such as a piece of tissue that is rolled to a desired diameter, a fabric roll or piece of material, a silicone piece, or some type of wire or tubular piece, for example. The shape of the structure 82 may be round, elliptical, or the like, and preferably does not provide sharp edges that contact the tissue. This seam protector 80 is shown as having a single layer, such as a tissue layer, since the structure 82 is intended to form the rounded area about which the tissue can bend and thus can be provided with a desired size and shape for the bend region. Alternatively, the seam protector 80 can have a multiple-layer construction, although the combined size of the material thickness along with the size of the structures 82 should be considered to arrive at a desired overall radius for this portion of the seam protector 80. All of these layers of material can then be stitched to each other, in a location that is spaced from the outer tubular wall, such as is shown by stitch 84.



FIG. 8 is another exemplary seam protection embodiment that is similar to that shown in both FIGS. 6 and 7 in that seam protector 90 includes an inverted U-shaped portion 92 from which U-shaped structures 94, 96 extend to create a sinusoidal shaped structure. In this embodiment, an additional layer of material 97, which can be tissue or fabric, for example, is inserted into the open area of the U-shaped structures 94, 96 to provide additional structural integrity to the area about which the tissue can bend. All of these layers of material can then be stitched to each other, in a location that is spaced from the outer tubular wall, such as is shown by stitch 98.



FIG. 9 is a perspective view of another seam protection embodiment that includes a seam protector 100 having a U-shaped portion 102 from which inverted U-shaped structures 104, 106 extend. In this embodiment, a flexible tube or other structure 108 is formed or curved into a U-shaped configuration and positioned in such a way that each of its ends extends into the open area of the structures 104, 106. The structure 108 is shown as having a generally circular cross-section, although a different shape for the structure 108 can be chosen, where the shape and size of the structure 108 will help to provide the shape about which the tissue of the valve assembly will bend. The material layers and seam protection components are attached to each other at a seam as shown by the exemplary stitching 110, which is spaced at a distance from the point where the material layers are under the greatest stress during operation of the valve.



FIG. 10 is a cross-sectional view of a seam protection feature incorporating a fabric or cloth material 120 that at least can be partially coated with silicone and cured into a sinusoidal shape. A wire 124 can be provided in the open area or areas of the sinusoidal shaped cloth piece. A quantity of silicone or other material 126 can be inserted into at least a portion of the open space(s) of the material 120 to at least partially surround the wire 124. A portion of a leaflet 122 is also shown relative to this seam protection feature.



FIGS. 11 and 12 illustrate multiple material or tissue layers at the seam of a valve assembly of the types described above, for example. In these embodiments, rather than covering the seam from the back, which may be difficult to secure due to the difficulty in precise placement of the tissue edges, the pieces can instead be secured or sewn separately and trimmed. In particular, the seam of FIG. 11 includes first and second seam protection side pieces (of the type generally shown in FIG. 1) on opposite sides of the multiple tissue layers of the valve tube and leaflets, along with a stitching line 130 that is spaced between the enlarged end of the first and second side pieces and the exposed or raw edges of tissue 134. The portion 132 of tissue extending between the stitching line 130 and the raw tissue edges 134 can be trimmed after sewing, if desired. Similarly, the portion of tissue 142 of FIG. 12 extending between the stitching line 140 and the raw edges of tissue 144 can be trimmed after sewing, if desired. In this embodiment, a piece of material or member 146 is wrapped with a tissue, fabric, or other sheet material 148 and attached on both sides of the seam to provide the surface about which the layers of tissue in the seam can bend. In order to join tissue prior to covering for seam protection, a laser weld can be used. Alternatively, the tissue layers can be “tack welded” together or secured to each other in some other manner.



FIGS. 46 and 47 illustrate a tube layer of material 150 and a layer of leaflet material 152 that have been stitched and configured in such a way that the tissue layers 150, 152 themselves create the seam protection. In particular, the two tissue layers are folded about a seam line and sewn along the stitch line 154 shown in FIG. 46. Padding or other material can be inserted in the area indicated as reference numeral 156 on one or both sides of the seam in FIG. 50 to provide additional seam protection. As shown in FIG. 47, a stitch 158 can be run through several of the layers of material to secure any padding or material in the area or areas 156 and to also secure the material layers to each other.



FIG. 13 illustrates one embodiment of a dovetail type of seam 160 for securing tissue and providing a non-abrasive hinging edge about which the tissue of the leaflets can flex. As shown in this embodiment, layers of tissue are provided with features that are engageable with each other in a locking manner.



FIG. 14 is another embodiment of a pericardial valve that includes outer tube layers 170, 171 and leaflets 172, 173, where this figure shows just one seam of a multiple leaflet valve. This embodiment further includes a wire 174 covered with a material layer 175 as shown in the Figure, which can be cloth or pericardium, for example. This layer 175 may be sewn along stitch line 176, for example, prior to it being attached to the tissue layers, where the wire can be bent and the wire ends can be cut or attached to a stent. The material layer 175 is sewn in the general area about which the leaflets will flex to enclose the wire and secure it to the valve. The layers of material may be stitched along stitch line 176, for example. The sewing area is chosen so that the stitches secure the covering of the wire (e.g., cloth or pericardium) to the seam allowance layers of the leaflets and outer tube layers 170, 171. FIG. 15 illustrates the seam allowance opened and folded back toward the outer tube layers 170, 171 of the valve.



FIG. 16 illustrates another embodiment of a seam of a valve assembly of the type described above. In particular, this embodiment illustrates outer tube portions 300, 302 and ends of leaflets 304, 306 positioned relative to each other in generally the manner described above. The embodiment further includes a seam protector or cover 310 that is stitched onto the seam allowance of the layers of the seam. The seam cover 310 can be semi-rigid to help protect the seam from wear. One exemplary way of manufacturing such a seam cover 310 is to mold it into a desired shape from silicone, Teflon, or the like.


A variety of exemplary shapes for seam covers and molds for making these seam covers are shown in FIGS. 17a-21b. In particular, FIG. 17a illustrates a seam cover 320 that has a generally uniform thickness and FIG. 17b shows a cross section of a mold 322 for making the seam cover 17a, which includes a notch 324 to provide easier folding of the seam cover. FIG. 18a shows another seam cover 330 that is relatively thin at the top area 332 to improve the ease of stitching it to the valve, and is thicker in the bottom area 334 to provide additional rigidity to the seam cover. The length of the thick portion 334 can vary depending on the desired distance of the seam from the inner portion of the heart valve. FIG. 18b shows a cross section of a mold 336 for making the seam cover 330 illustrated in FIG. 18a. Another seam cover 340 is illustrated in FIG. 19a, which is relatively thin at the top or bend area 342 to provide ease in stitching it to the valve, and tapers to be thicker toward the free edges 344 to provide additional rigidity to the seam cover 340. FIG. 19b shows a cross section of a mold 346 for making the seam cover 340 illustrated in FIG. 19a. FIG. 20a illustrates another seam cover 350 that is relatively thin at the top area 352 and has knob portions 354 at its free edges. FIG. 20b shows a cross section of a mold 356 for making the seam cover 350 illustrated in FIG. 20a. Finally, FIG. 21a is a cross-sectional view of another seam cover 360 that includes notches 362, 364 on opposite sides, where the notch 362 on the outside is to provide ease in folding the seam cover 360 and the notch 364 on the inside is provided to accommodate the thickness of the tissue. FIG. 21b shows a cross-sectional view of a mold 366 for making the seam cover 360 illustrated in FIG. 21a.


When stitching any of the seam covers described above to the seam of a valve, it may be desirable to use a template; however, in order to use a template for a seam cover (which may be made of silicone or the like) while also minimizing the bulkiness of the seam, enough surface area should be provided for clamping the materials onto the template. That is, the width of the seam cover can be increased to be at least slightly larger than necessary, and the extra material can be trimmed away after the seam has been stitched.



FIG. 22 shows another seam configuration of a heart valve in accordance with the invention, which includes leaflets 190 and an outer layer 192 of tube on each side of the seam. The seam further includes a relatively rigid insert 194 on each side of the seam. The inserts 194 can be polymer strips having a series of stitching holes, for example, or may have another configuration. The seam further includes another insert 196 that can be relatively soft compared to the more rigid inserts 194 and can be made out of a tissue or fabric roll, rope, or braid, for example. However, the relative rigidity of the inserts can vary widely, depending on the desired characteristics for the valve. Insert 196 can be designed to fill the space between the tissue layers and create tension in a back panel 198 by pulling the inserts 194 toward one another and capturing the leaflets against a relatively soft hinging surface. The back panel 198 can be a relatively flexible sheet of material such as pericardium, fabric, or a synthetic material. The back panel 198 can be attached with a blanket or whip stitch, for example, as shown by reference number 204. This stitching can extend through the back panel 198 and through the insert 196 in order to remove slack in the back panel 198, create tension, and pull the inserts 194 toward each other. Optional sewing along one or more stitch lines 200 on both sides of the seam can extend through all the layers to encase the inserts 194. Sewing along optional stitch lines 202 on both sides of the seam will extend only through the inserts 194, the back panel 198, and the seam allowance layers. The valve can be attached to a stent at this seam by sewing through the back panel 198, which can provide compliance between the relatively rigid stent and the relatively flexible valve. Alternatively, the back panel 198 can be eliminated from the construction and any rigid inserts 194 can be whip or blanket stitched together. The use of these inserts 194 encased by the outer tube layer 192, when secured end to end as shown, provide a nonabrasive hinging region for the leaflets of the seam. In addition, this seam configuration moves the leaflet hinge or pivot point away from the leaflet/stent or valve attachment point by pulling the leaflet/rigid insert seam toward the stent, away from the inside of the valve, and securing it in place by attaching the back panel to the leaflet and tube seam allowances and rigid inserts.



FIG. 23 illustrates two layers of pericardium 216 and two relatively rigid inserts 212 used in a seam construction. In particular, the layers 216 are sewn to each other along line 210 to create the margin of attachment of a leaflet. The free margin is cut along line 214, which is shown as a hidden line, since that cut would be through the bottom layer shown in the figure. The inserts 212 are sewn to the outside layer and in some embodiments are also sewn to the leaflet layer. At least one end of each of the inserts 212 is preferably rounded so that the transition between the margin of attachment stitches and the inserts 212 is smooth. The inserts 212 are positioned so that the margin of attachment stitches are generally tangential to the edge of the inserts. Three of these constructions can be used in making a tri-leaflet valve.



FIGS. 24-27 illustrate several exemplary seam constructions, some of which are similar to those discussed above and therefore can include the variations and features discussed above relative to seams for pericardial heart valve constructions. All of these seam constructions are provided as ways to reduce or eliminate exposure of the stitches to the inside of the valve and the blood stream, while minimizing the size of the seam. FIG. 24 shows a seam construction 400 that uses generally cylindrical pieces of material 402, such as rolled or folded pericardium, PTFE, silicone, or the like, which is stitched to the layers of tissue of the seam. The portion of each material piece closest to the valve is fairly rigid and may allow the leaflets to flex at the material piece rather than at the stitches. The size of the material pieces 402 should be as small as possible to minimize the size of the seam, but large enough to keep rigidity and allow the leaflets to flex around them. The material pieces 402 are also preferably flexible enough that they can be crimped down with the stent without compromising the security of the stitching.



FIG. 25 illustrates a variation 408 of the seam construction of FIG. 24. The construction of FIG. 25 includes material pieces 410 that are more triangular in shape to improve the flexibility at the flex point and prevent the seam from opening up to expose the sutures to the inside of the tube. FIG. 26 illustrates another exemplary seam construction 420 that includes rolling the free end of an outer tube material 422 on itself to make a coil of material 424 (e.g., pericardial tissue). When sewing the seam, the stitches can be positioned to penetrate through some or all of the layers of material of the coil 424. This construction 420 advantageously utilizes material that is already part of the valve construction and therefore does not require additional separate elements. In this embodiment, the length of the pieces of outer tube material 422 should be long enough to provide sufficient material to make the coil of material 424. FIG. 27 illustrates yet another seam construction 430 of a heart valve that includes folding a free edge of an outer tube material 432 on itself to create at least one loop of material 434 at the area about which the leaflets will flex. A wire or other material can be inserted into the loop of material nearest the outer tube layer 432 to give a more rounded shape to this portion. The free ends of the outer tube layer 432 can be trimmed to minimize the bulkiness of the seam, if desired.



FIGS. 28 and 29 show two seam constructions that are particularly configured to minimize or eliminate exposure of the sutures to the inside of the valve. FIG. 28 shows leaflets 220 and a center loop or piece of material 222 (e.g., pericardial tissue) that are situated relative to each other so that the leaflets 220 can flex about the points “a” and “b”. Because the center material 222 would not be flexing, there will not be a large gap at these points, thereby minimizing exposure of the inside of the valve to the seam. FIG. 29 illustrates a seam that is similar to that of FIG. 28, but also includes an additional piece of material 234 between the layers of a material loop 232. This material piece 234 is preferably designed to even better improve the quality of the seal between the material loop 232 and the leaflets 230 to minimize exposure of the inside of the valve to the seam.


Additional seam constructions are illustrated in FIGS. 30-32, which provide a strip for seam support and an element about which leaflets 444, 446 can bend. In particular, FIG. 30 shows a main seam 440 (indicated by dashed lines) and a strip of rigid “balls” 442 sewn into the construction at a line about which leaflets 444, 446 can flex. The spacing of these balls 442 from each other can be similar to that shown, or the balls 442 can be closer to or further from each other as compared to the figure. FIG. 31 shows a construction similar to that of FIG. 35. In this embodiment, the main seam and the rigid ball support strip 450 are on the same stitch line. With both of these embodiments of FIGS. 30 and 31, it can be advantageous for the balls to be very close to each other when the valve is in its expanded condition, but that the balls are further from each other when the valve is crimped or compressed due to the elongation of the valve. This is different from a solid strip, which can also be used in this area, in that the balls can move away from each other during compression, while a solid strip would need to stretch during a similar compression.


In the top schematic view of FIG. 32, one ball 452 of a strip is shown as being oblong in shape, where the strip can include a series of balls, and stitching extends through each of the oblong-shaped balls. The balls of these constructions can be plastic, metal, or another material and can be preformed, or the balls can be formed by placing fast-curing drops of material along the desired sewing line. The balls 452 may also have a different shape other than spherical, elliptical, and the like.


A variety of sewing strips can be used in combination with other features of the invention relative to seam construction, or the sewing strips that are shown and described herein relative to FIGS. 33-36 can be used alone or with other seam constructions. In any case, the sewing strips can be provided along a seam line for stitch and seam support and are preferably as small as possible to minimize bulk in the seam area, while still providing desired properties for the seam support. The sewing strips may include one strip that extends the entire height of the valve, or a series of strips may be used so that they can move relative to each other during elongation caused by stent crimping. One exemplary sewing strip shape is illustrated in FIG. 33 with the L-shaped strips 250, one of which is also shown in FIG. 34, positioned on opposite side of leaflets 252. Note that this embodiment does not include an outer tube, although these sewing strips can also be used with valve constructions that do include an outer tube. In order to also accommodate the diamond-shape of some stent struts, the sewing strip could instead be configured as shown in FIGS. 35 and 36 as strips 260, 262. In this configuration, triangular shaped extensions are designed to follow the strut pattern of the stent to which the valve will be attached. With any of the sewing strips, the material from which the sewing strip is made can be relatively flexible to allow for variations in the stent dimensions. Any of the sewing strips may be made of a silicone, rubber, another extruded polymer, pericardial material, and the like.



FIGS. 37-42 illustrate various configurations of placement of a roll or strip of material along the seam of a leaflet margin of attachment so that the leaflet flexes about the roll or strip of material rather than the high stress area of the suturing or sewing line. FIGS. 37 and 38 show a construction that does not include such a strip of material, but includes a suture 500 that attaches a leaflet 502 directly to a tube wall 504 such that as the leaflet 502 opens and closes, the tissue flexes directly about the suture 500 at the areas designated by reference numbers 506 and 508. A preferred direction for the inflow of blood is indicated by arrow 510. FIG. 39 adds a roll or strip of material 520 to the basic construction of FIG. 37, where this roll or strip of material 520 provides an element about which the leaflets 502 can flex. FIG. 40 shows a valve in a closed position with the roll of material 520 illustrated as being positioned on top of the leaflets. FIGS. 41 and 42 include two rolls or strips of material 520, with the strips of material 520 located on opposite sides of the leaflet 502 so that the leaflets 502 can flex about these strips of material 520.



FIG. 43 is a top view of a valve construction 530 that includes a layer of cloth 532 (e.g. cloth available under the trade designation “Dacron”) between the stent and the valve tissue. The cloth layer could be sewn or otherwise attached to a stent, then the tissue tube could be sewn or attached to only the cloth layer. In this way, when the stent is crimped, the cloth layer can stretch with the stent and the tissue will either (a) not stretch, or (b) stretch less than if the cloth layer was not included in the construction. That is, the cloth layer can help to minimize the stresses on the tissue and keep it from needing to deform excessively when the stent is compressed and expanded.



FIG. 44 is another alternate construction of a pericardial valve that starts with a sheet of pericardium from which a disc of material 540 is cut. A hole 542 is then cut in the center of the disc, where the size of the center hole is the same as the inner diameter of a selected valve size. This inner hole 542 is sewn or otherwise attached to the inflow side of a stent frame (not shown). A plate or other fixture can then be used to form the leaflet shapes 544 (see FIG. 45) by pressing the flat sheet of tissue between plates, then fixing the material in one of the manners described herein and/or in a manner commonly known in the art for fixing pericardial material. Alternatively, the leaflets 544 can be shaped after placing the material on a stent. In either case, the tissue in between the leaflet forms would then be pulled through slots of a stent form and attached on the outside of the stent.


In many of the embodiments described herein, the pericardial valve is prepared to include three leaflets, but may optionally have more or less than three leaflets, which can be formed by selecting the desired number of leaflet and outer tube components. The three leaflet embodiment can be used in areas of the heart that typically have a three leaflet valve, such as the pulmonary valve and aortic valve, although the three leaflet embodiment can also be used as a replacement for the two leaflet mitral valve. Alternatively, a two leaflet or single leaflet embodiment of the valve of the invention is contemplated, which can be used in areas of the heart that typically have a three leaflet valve, such as the pulmonary valve, for example. Certain considerations for blood flow will determine particular parameters of the valve used, as will be explained in further detail below.


The valve constructions of the invention may be used alone as a stentless valve, or the valve segments may be attached to a support structure such as a stent. The stent may be compressible for percutaneous delivery to the heart of a patient, for example. The stent used may take the form of a series of zig-zag ring structures and may be fabricated of platinum, stainless steel, or other biocompatible metal or polymer. The stent used may alternatively be fabricated using wire stock or may be produced by machining the stent from a metal tube, as is commonly employed in the manufacturing of stents. The number of wires, the positioning of such wires, and various other features of the stent chosen can vary considerably. Thus, the specifics of the stent can vary widely, such that many other known generally cylindrical stent configurations may be used within the scope of the invention. A series of zig-zag ring structures can be coupled longitudinally to one another to form a generally cylindrical-shaped structure, although it is understood that the structures can be arranged in an at least slightly oval or elliptical shape. Each ring structure can take the form of a series of adjacent generally straight sections, which each meet one another at one end at a curved or angled junction to form a “V” or “U” shaped structure.


Once a valve segment and stent are positioned relative to each other, the stent can be secured to the valve segment in a variety of ways. One procedure that can be used is to suture certain areas of the stent to the valve segment. The suture material may be provided as a monofilament or multifilament structure made of natural or synthetic materials (e.g., nylon or polypropylene), or may alternatively include an elongated metal or metal-composite thread or filament that is suitable for permanently securing the stent to the valve segment in accordance with the present invention. The number and location of suture points can vary, but should include an adequate number of connection points that are positioned in predetermined locations that prevent movement of the stent relative to the valve segment, particularly during the compression of the stent for percutaneous delivery and expansion of the stent for its deployment.


The valves or stented valves of the invention can be subjected to suitable chemical fixation and/or bioburden reduction treatments, which may vary considerably. Chemical fixation helps to preserve the tissue, render it inert, reduce the risk of host rejection, and/or the like. Chemical fixation may occur by submerging the valve in a suitable reagent for a period of about 3 hours under slight pressure and ambient temperature and then for 72 hours under ambient pressure and temperature. By way of example, a 0.2 weight percent gluteraldehyde solution at physiological pH and being phosphate buffered may be used for chemical fixation. The valve may then be stored in a suitable storage reagent (e.g., an aqueous solution containing 0.2% by weight gluteraldehyde) until subsequent use. Bioburden reduction may be carried out by submerging the tissue in a suitable reagent for a period of 48 to 72 hours at ambient temperature. By way of example, an aqueous solution containing 1% by weight gluteraldehyde and 20% by weight isopropyl alcohol at physiological pH and being phosphate-buffered may be used for bioburden reduction. This solution would be suitable for use as a packaging solution as well. A variety of fixation tines, concentrations, pH levels and chemicals can be used in accordance with the invention. After suitable treatments to the valve are complete and after appropriate rinsing of the valve, the device can be used for implantation into a human.


When valves of the invention are made into a stented valve, the stented valves may be used with a system for delivering the valve segment to the desired location within a patient. The delivery system may include, for example, an outer sheath overlying an inner balloon catheter, where the outer sheath includes an expanded distal portion, within which the stented valve is located. The stented valve can be compressed around a single or double balloon located on the inner catheter. A tapered tip mounted to the distal end of the inner catheter can ease the passage of the delivery system through the patient's vasculature. The system also may include some type of guidewire to guide the delivery system to its desired implant location. Another alternative delivery system that can be used, in particular, for stented valves having a self-expanding stent, includes a catheter that does not have balloons, but instead includes a sheath or other mechanism that maintains the self-expanding stent in its compressed condition until it is desired to allow it to expand. When such a self-expanding stent is properly positioned in the patient, the mechanism that keeps the stent compressed can be retracted or otherwise removed to allow for expansion of the stent against the vessel walls.


The delivery system and its use may be used where the stented valve can be expanded against a failed native or prosthetic valve. The delivery system can be advanced to the desired valve implant site using the guidewire, after which the sheath is moved proximally, exposing the valve and balloon mounted on inner catheter. The balloon is expanded, which thereby expands stented valve until it reaches a desired outer diameter where it contacts the wall of a heart vessel. The balloon is then deflated and the delivery system is withdrawn proximally.


The present invention has now been described with reference to several embodiments thereof. The entire disclosure of any patent or patent application identified herein is hereby incorporated by reference. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. It will be apparent to those skilled in the art that many changes can be made in the embodiments described without departing from the scope of the invention. Thus, the scope of the present invention should not be limited to the structures described herein, but only by the structures described by the language of the claims and the equivalents of those structures.

Claims
  • 1. A multi-leaflet heart valve defining a lumen, the heart valve comprising; a first leaflet having first and second sides;a second leaflet having first and second sides, wherein the first side of an end portion of the first leaflet is adjacent to the first side of an end portion of the second leaflet;a first outer tube layer having first and second sides, wherein the first side of an end portion of the first outer tube layer is adjacent to the second side of the end portion of the first leaflet;a second outer tube layer having first and second sides, wherein the first side of an end portion of the second outer tube is adjacent to the second side of the end portion of the second leaflet; anda first seam protector adjacent to and lying along at least a portion of the surface of the second side of the first outer tube layer;wherein the first seam protector comprises a first curved surface facing the lumen of the heart valve, the first curved surface being positioned along a line about which the first leaflet will flex;wherein the first seam protector comprises an enlarged cylindrical portion and an extending linear portion, wherein the cylindrical portion defines the first curved surface.
  • 2. The valve of claim 1, further comprising a second seam protector; wherein the second seam protector is adjacent to the first seam protector;wherein the second seam protector is adjacent to and lying along at least a portion of the surface of the second side of the second outer tube layer; andwherein the second seam protector comprises a second curved surface facing the lumen of the heart valve, the second curved surface being positioned along a line about which the second leaflet will flex.
  • 3. The valve of claim 2, wherein each of the first and second seam protectors comprises a first end, a second end, and multiple sewing holes, wherein the sewing holes are sized and spaced between the first and second ends of the seam protector at a predetermined distance from first and second flexure lines about which the first and second leaflets will open and close, respectively.
  • 4. The valve of claim 1, further comprising a third leaflet, wherein the valve comprises three seams.
  • 5. The valve of claim 1, wherein at least one of the first and second leaflets and the first and second outer tube layers comprise a sheet of pericardial material.
  • 6. The valve of claim 1, wherein the first seam protector is at least slightly more rigid than each of the first and second leaflets and the first and second outer tube layers.
  • 7. The valve of claim 6, wherein the first seam protector comprises at least one of silicone, reinforced silicone, and plastic.
  • 8. The valve of claim 7, wherein each of the first and second leaflets and the first and second outer tube layers is formed from one of a sheet of pericardium material, a polymer film, and a bio-engineered film.
  • 9. The valve of claim 1, further comprising: a third leaflet having first and second sides, wherein the first side of an end portion of the second leaflet is adjacent to the first side of an end portion of the third leaflet;a third outer tube layer having first and second sides, wherein the first side of an end portion of the third outer tube layer is adjacent to the second side of the end portion of the third leaflet; anda third seam protector adjacent to and lying along at least a portion of the surface of the second side of the second outer tube layer.
  • 10. A prosthetic heart valve defining a lumen, the heart valve comprising: a first tissue layer having first and second sides;a second tissue layer having first and second sides, wherein the first side of the first tissue layer is adjacent to the first side of the second tissue layer to form a seam of the heart valve; anda first seam protector adjacent to and lying along at least a portion of the surface of the second side of the second tissue layer, the first seam protector comprising a first enlarged cylindrical portion and a first extending linear portion, wherein the first cylindrical portion defines a first curved surface facing the lumen of the heart valve and positioned along a line about which the second tissue layer flexes.
  • 11. The heart valve of claim 10, further comprising a second seam protector, the first and second tissue layers being positioned between the first and second seam protectors.
  • 12. The heart valve of claim 11, wherein the second seam protector comprises a second enlarged cylindrical portion and a second extending linear portion, wherein the second cylindrical portion defines a second curved surface facing the lumen of the heart valve.
  • 13. The heart valve of claim 10, wherein the first seam protector comprises a first end, a second end, and multiple sewing holes, wherein the sewing holes are sized and spaced between the first and second ends of the first seam protector at a predetermined distance from a flexure line about which the second tissue layer will flex.
  • 14. The heart valve of claim 10, wherein the first seam protector is at least slightly more rigid than each of the first and second tissue layers.
  • 15. The heart valve of claim 14, wherein the first seam protector comprises at least one of silicone, reinforced silicone, and plastic.
  • 16. The heart valve of claim 10, wherein each of the first and second tissue layers comprises pericardium.
CROSS-REFERENCE TO RELATED APPLICATION

The present application claims priority to U.S. Provisional Application Nos. 61/125,203, filed Apr. 23, 2008, and titled “Tissue Attachment Devices and Methods for Prosthetic Heart Valves” the entire contents of which is incorporated herein by reference in its entirety.

US Referenced Citations (553)
Number Name Date Kind
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3755823 Hancock Sep 1973 A
3868956 Alfidi et al. Mar 1975 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4106129 Carpentier et al. Aug 1978 A
4192020 Davis et al. Mar 1980 A
4222126 Boretos et al. Sep 1980 A
4265694 Boretos May 1981 A
4297749 Davis et al. Nov 1981 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4388735 Ionescu et al. Jun 1983 A
4425908 Simon Jan 1984 A
4441216 Ionescu et al. Apr 1984 A
4470157 Love Sep 1984 A
4501030 Lane Feb 1985 A
4574803 Storz Mar 1986 A
4580568 Gianturco Apr 1986 A
4592340 Boyles Jun 1986 A
4610688 Silvestrini et al. Sep 1986 A
4647283 Carpentier et al. Mar 1987 A
4648881 Carpentier et al. Mar 1987 A
4665906 Jervis May 1987 A
4681908 Broderick et al. Jul 1987 A
4710192 Liotta et al. Dec 1987 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4819751 Shimada et al. Apr 1989 A
4834755 Silvestrini et al. May 1989 A
4856516 Hillstead Aug 1989 A
4872874 Taheri Oct 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4909252 Goldberger Mar 1990 A
4917102 Miller et al. Apr 1990 A
4922905 Strecker May 1990 A
4994077 Dobben Feb 1991 A
5002559 Tower Mar 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5059177 Towne et al. Oct 1991 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5161547 Tower Nov 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5217483 Tower Jun 1993 A
5232445 Bonzel Aug 1993 A
5272909 Nguyen et al. Dec 1993 A
5295958 Shturman Mar 1994 A
5327774 Nguyen et al. Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5350398 Pavcnik et al. Sep 1994 A
5370685 Stevens Dec 1994 A
5389106 Tower Feb 1995 A
5397351 Pavcnik et al. Mar 1995 A
5411552 Andersen et al. May 1995 A
5415633 Lazarus et al. May 1995 A
5431676 Dubrul et al. Jul 1995 A
5443446 Shturman Aug 1995 A
5480424 Cox Jan 1996 A
5489294 McVenes et al. Feb 1996 A
5489297 Duran Feb 1996 A
5496346 Horzewski et al. Mar 1996 A
5500014 Quijano et al. Mar 1996 A
5507767 Maeda et al. Apr 1996 A
5545209 Roberts et al. Aug 1996 A
5545211 An et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5554185 Block et al. Sep 1996 A
5575818 Pinchuk Nov 1996 A
5580922 Park et al. Dec 1996 A
5591195 Taheri et al. Jan 1997 A
5609626 Quijano et al. Mar 1997 A
5645559 Hachtman et al. Jul 1997 A
5667523 Bynon et al. Sep 1997 A
5674277 Freitag Oct 1997 A
5702368 Stevens et al. Dec 1997 A
5713953 Vallana et al. Feb 1998 A
5716417 Girard et al. Feb 1998 A
5746709 Rom et al. May 1998 A
5749890 Shaknovich May 1998 A
5766151 Valley et al. Jun 1998 A
5782809 Umeno et al. Jul 1998 A
5800456 Maeda et al. Sep 1998 A
5800508 Goicoechea et al. Sep 1998 A
5817126 Imran Oct 1998 A
5824041 Lenker Oct 1998 A
5824043 Cottone, Jr. Oct 1998 A
5824053 Khosravi et al. Oct 1998 A
5824056 Rosenberg Oct 1998 A
5824061 Quijano et al. Oct 1998 A
5824064 Taheri Oct 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5860966 Tower Jan 1999 A
5861028 Angell Jan 1999 A
5868783 Tower Feb 1999 A
5891191 Stinson Apr 1999 A
5895419 Tweden et al. Apr 1999 A
5906619 Olson et al. May 1999 A
5913842 Boyd et al. Jun 1999 A
5925063 Khosravi Jul 1999 A
5957949 Leonhardt et al. Sep 1999 A
5968068 Dehdashtian et al. Oct 1999 A
5984957 Laptewicz, Jr. et al. Nov 1999 A
5997573 Quijano et al. Dec 1999 A
6022370 Tower Feb 2000 A
6027525 Suh et al. Feb 2000 A
6029671 Stevens et al. Feb 2000 A
6042589 Marianne Mar 2000 A
6042598 Tsugita et al. Mar 2000 A
6042607 Williamson, IV Mar 2000 A
6051014 Jang Apr 2000 A
6059809 Amor et al. May 2000 A
6110201 Quijano et al. Aug 2000 A
6146366 Schachar Nov 2000 A
6159239 Greenhalgh Dec 2000 A
6162245 Jayaraman Dec 2000 A
6171335 Wheatley et al. Jan 2001 B1
6200336 Pavcnik et al. Mar 2001 B1
6203550 Olson Mar 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6218662 Tchakarov et al. Apr 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6245102 Jayaraman Jun 2001 B1
6248116 Chevilon Jun 2001 B1
6258114 Konya et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258120 McKenzie et al. Jul 2001 B1
6277555 Duran et al. Aug 2001 B1
6299637 Shaolia et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6309382 Garrison et al. Oct 2001 B1
6309417 Spence et al. Oct 2001 B1
6338735 Stevens Jan 2002 B1
6348063 Yassour et al. Feb 2002 B1
6350277 Kocur Feb 2002 B1
6352708 Duran et al. Mar 2002 B1
6371970 Khosravi et al. Apr 2002 B1
6371983 Lane Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6398807 Chouinard et al. Jun 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6475239 Campbell et al. Nov 2002 B1
6482228 Norred Nov 2002 B1
6488704 Connelly et al. Dec 2002 B1
6494909 Greenhalgh Dec 2002 B2
6503272 Duerig et al. Jan 2003 B2
6508833 Pavcnik et al. Jan 2003 B2
6527800 McGuckin, Jr. et al. Mar 2003 B1
6530949 Konya et al. Mar 2003 B2
6530952 Vesely Mar 2003 B2
6562031 Chandrasekaran et al. May 2003 B2
6562058 Seguin et al. May 2003 B2
6569196 Vesely May 2003 B1
6585758 Chouinard et al. Jul 2003 B1
6592546 Barbut et al. Jul 2003 B1
6605112 Moll et al. Aug 2003 B1
6613077 Gilligan et al. Sep 2003 B2
6622604 Chouinard et al. Sep 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6652571 White et al. Nov 2003 B1
6652578 Bailey et al. Nov 2003 B2
6656213 Solem Dec 2003 B2
6673109 Cox Jan 2004 B2
6676698 McGuckin, Jr. et al. Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6685739 DiMatteo et al. Feb 2004 B2
6689144 Gerberding Feb 2004 B2
6689164 Seguin Feb 2004 B1
6692512 Jang Feb 2004 B2
6692513 Streeter et al. Feb 2004 B2
6695878 McGuckin, Jr. et al. Feb 2004 B2
6702851 Chinn et al. Mar 2004 B1
6719789 Cox Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6730377 Wang May 2004 B2
6733525 Yang et al. May 2004 B2
6736846 Cox May 2004 B2
6752828 Thornton Jun 2004 B2
6769434 Liddicoat et al. Aug 2004 B2
6786925 Schoon Sep 2004 B1
6790229 Berreklouw Sep 2004 B1
6792979 Konya et al. Sep 2004 B2
6797002 Spence Sep 2004 B2
6821297 Snyders Nov 2004 B2
6830575 Stenzel et al. Dec 2004 B2
6830584 Seguin Dec 2004 B1
6830585 Artof Dec 2004 B1
6846325 Liddicoat Jan 2005 B2
6866650 Stevens Mar 2005 B2
6872223 Roberts Mar 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6883522 Spence et al. Apr 2005 B2
6887266 Williams et al. May 2005 B2
6890330 Streeter et al. May 2005 B2
6893460 Spenser et al. May 2005 B2
6896690 Lambrecht et al. May 2005 B1
6908481 Cribier Jun 2005 B2
6913600 Valley et al. Jul 2005 B2
6929653 Streeter Aug 2005 B2
6939365 Fogarty et al. Sep 2005 B1
6951571 Srivastava Oct 2005 B1
6986742 Hart et al. Jan 2006 B2
6989027 Allen et al. Jan 2006 B2
6989028 Lashinski et al. Jan 2006 B2
6991649 Sievers Jan 2006 B2
7018401 Hyodoh et al. Mar 2006 B1
7041128 McGuckin, Jr. et al. May 2006 B2
7044966 Svanidze et al. May 2006 B2
7048014 Hyodoh et al. May 2006 B2
7097659 Woolfson et al. Aug 2006 B2
7101396 Artof et al. Sep 2006 B2
7105016 Shui et al. Sep 2006 B2
7115141 Menz et al. Oct 2006 B2
7147663 Berg et al. Dec 2006 B1
7153324 Case et al. Dec 2006 B2
7160319 Chouinard et al. Jan 2007 B2
7175656 Khairkhahan Feb 2007 B2
7186265 Sharkawy et al. Mar 2007 B2
7195641 Palmaz et al. Mar 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201761 Woolfson et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7252682 Seguin Aug 2007 B2
7300457 Palmaz Nov 2007 B2
7300463 Liddicoat Nov 2007 B2
7316706 Bloom et al. Jan 2008 B2
7329278 Seguin Feb 2008 B2
7335218 Wilson et al. Feb 2008 B2
7338520 Bailey et al. Mar 2008 B2
7374571 Pease et al. May 2008 B2
7381218 Schreck Jun 2008 B2
7384411 Condado Jun 2008 B1
7429269 Schwammenthal et al. Sep 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
7462191 Spenser et al. Dec 2008 B2
7470284 Lambrecht et al. Dec 2008 B2
7473275 Marquez Jan 2009 B2
7481838 Carpentier et al. Jan 2009 B2
7544206 Cohn et al. Jun 2009 B2
7556646 Yang et al. Jul 2009 B2
7628805 Spenser et al. Dec 2009 B2
7758640 Vesely Jul 2010 B2
8052750 Tuval et al. Nov 2011 B2
8500798 Rowe et al. Aug 2013 B2
8568475 Nguyen et al. Oct 2013 B2
20010001314 Davison et al. May 2001 A1
20010002445 Vesely May 2001 A1
20010007956 Letac et al. Jul 2001 A1
20010010017 Letac et al. Jul 2001 A1
20010011189 Drasler et al. Aug 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010025196 Chinn et al. Sep 2001 A1
20010032013 Marton Oct 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20010041928 Pavcnik et al. Nov 2001 A1
20010044647 Pinchuk et al. Nov 2001 A1
20020010508 Chobotov Jan 2002 A1
20020029014 Jayaraman Mar 2002 A1
20020032480 Spence et al. Mar 2002 A1
20020032481 Gabbay Mar 2002 A1
20020035396 Heath Mar 2002 A1
20020042650 Vardi et al. Apr 2002 A1
20020052651 Myers et al. May 2002 A1
20020058995 Stevens May 2002 A1
20020072789 Hackett et al. Jun 2002 A1
20020099439 Schwartz et al. Jul 2002 A1
20020103533 Langberg et al. Aug 2002 A1
20020107565 Greenhalgh Aug 2002 A1
20020111674 Chouinard et al. Aug 2002 A1
20020123802 Snyders Sep 2002 A1
20020133183 Lentz et al. Sep 2002 A1
20020133226 Marquez et al. Sep 2002 A1
20020138138 Yang Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020161392 Dubrul Oct 2002 A1
20020161394 Macoviak et al. Oct 2002 A1
20020193871 Beyersdorf et al. Dec 2002 A1
20030014104 Cribier Jan 2003 A1
20030023300 Bailey et al. Jan 2003 A1
20030023303 Palmaz et al. Jan 2003 A1
20030028247 Cali Feb 2003 A1
20030036791 Philipp et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030040792 Gabbay Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030065386 Weadock Apr 2003 A1
20030109924 Cribier Jun 2003 A1
20030125795 Pavcnik et al. Jul 2003 A1
20030130726 Thorpe et al. Jul 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030139804 Hankh et al. Jul 2003 A1
20030149475 Hyodoh et al. Aug 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030149478 Figulla et al. Aug 2003 A1
20030153974 Spenser et al. Aug 2003 A1
20030181850 Diamond et al. Sep 2003 A1
20030191519 Lombardi et al. Oct 2003 A1
20030199913 Dubrul et al. Oct 2003 A1
20030199963 Tower et al. Oct 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030212410 Stenzel et al. Nov 2003 A1
20030212454 Scott et al. Nov 2003 A1
20040034411 Quijano et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040049224 Buehlmann et al. Mar 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040082904 Houde et al. Apr 2004 A1
20040088045 Cox May 2004 A1
20040093005 Durcan May 2004 A1
20040093060 Sequin et al. May 2004 A1
20040097788 Mourles et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040106976 Bailey et al. Jun 2004 A1
20040106990 Spence et al. Jun 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040116951 Rosengart Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040122516 Fogarty Jun 2004 A1
20040127979 Wilson Jul 2004 A1
20040138742 Myers et al. Jul 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040153146 Lashinski et al. Aug 2004 A1
20040167573 Williamson Aug 2004 A1
20040167620 Ortiz Aug 2004 A1
20040186563 Iobbi Sep 2004 A1
20040193261 Berreklouw Sep 2004 A1
20040210240 Saint Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215333 Duran Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040225353 McGuckin, Jr. Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20040260394 Douk et al. Dec 2004 A1
20040267357 Allen et al. Dec 2004 A1
20050010246 Streeter Jan 2005 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050010287 Macoviak Jan 2005 A1
20050015112 Cohn et al. Jan 2005 A1
20050027348 Case et al. Feb 2005 A1
20050033398 Seguin Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050049692 Numamoto Mar 2005 A1
20050049696 Siess Mar 2005 A1
20050055088 Liddicoat et al. Mar 2005 A1
20050060029 Le Mar 2005 A1
20050060030 Lashinski et al. Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075712 Biancucci Apr 2005 A1
20050075717 Nguyen Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075724 Svanidze Apr 2005 A1
20050075727 Wheatley Apr 2005 A1
20050075730 Myers Apr 2005 A1
20050075731 Artof Apr 2005 A1
20050085841 Eversull et al. Apr 2005 A1
20050085842 Eversull et al. Apr 2005 A1
20050085843 Opolski et al. Apr 2005 A1
20050085890 Rasmussen et al. Apr 2005 A1
20050085900 Case et al. Apr 2005 A1
20050096568 Kato May 2005 A1
20050096692 Linder et al. May 2005 A1
20050096724 Stenzel et al. May 2005 A1
20050096734 Majercak et al. May 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096736 Osse et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050096739 Cao May 2005 A1
20050107871 Realyvasquez et al. May 2005 A1
20050113910 Paniagua May 2005 A1
20050119688 Bergheim Jun 2005 A1
20050131438 Cohn Jun 2005 A1
20050137686 Salahieh Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137692 Haug Jun 2005 A1
20050137695 Salahieh Jun 2005 A1
20050137701 Salahieh Jun 2005 A1
20050143809 Salahieh Jun 2005 A1
20050148997 Valley et al. Jul 2005 A1
20050149181 Eberhardt Jul 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050187616 Realyvasquez Aug 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203605 Dolan Sep 2005 A1
20050203618 Sharkawy Sep 2005 A1
20050222674 Paine Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050234546 Nugent Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240263 Fogarty et al. Oct 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050283962 Boudjemline Dec 2005 A1
20060004439 Spenser et al. Jan 2006 A1
20060009841 McGuckin et al. Jan 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060058775 Stevens et al. Mar 2006 A1
20060089711 Dolan Apr 2006 A1
20060100685 Seguin et al. May 2006 A1
20060116757 Lashinski et al. Jun 2006 A1
20060135964 Vesely Jun 2006 A1
20060142848 Gabbay Jun 2006 A1
20060167474 Bloom et al. Jul 2006 A1
20060178740 Stacchino et al. Aug 2006 A1
20060195134 Crittenden Aug 2006 A1
20060206192 Tower et al. Sep 2006 A1
20060206202 Bonhoefer et al. Sep 2006 A1
20060217802 Ruiz et al. Sep 2006 A1
20060229719 Marquez et al. Oct 2006 A1
20060247763 Slater Nov 2006 A1
20060259134 Schwammenthal et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060265056 Nguyen et al. Nov 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060271175 Woolfson et al. Nov 2006 A1
20060276874 Wilson et al. Dec 2006 A1
20060282161 Huynh et al. Dec 2006 A1
20070005129 Damm et al. Jan 2007 A1
20070005131 Taylor Jan 2007 A1
20070010878 Rafiee et al. Jan 2007 A1
20070016286 Herrmann et al. Jan 2007 A1
20070016288 Gurskis et al. Jan 2007 A1
20070027518 Case et al. Feb 2007 A1
20070027533 Douk Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070051377 Douk et al. Mar 2007 A1
20070073392 Heyninck-Jantz Mar 2007 A1
20070078509 Lotfy et al. Apr 2007 A1
20070078510 Ryan Apr 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070093869 Bloom et al. Apr 2007 A1
20070100439 Cangialosi May 2007 A1
20070100440 Figulla May 2007 A1
20070100449 O'Neil et al. May 2007 A1
20070112415 Bartlett May 2007 A1
20070162102 Ryan et al. Jul 2007 A1
20070162113 Sharkawy et al. Jul 2007 A1
20070185513 Woolfson et al. Aug 2007 A1
20070203391 Bloom et al. Aug 2007 A1
20070208550 Cao et al. Sep 2007 A1
20070225681 House Sep 2007 A1
20070232898 Huynh et al. Oct 2007 A1
20070233228 Eberhardt et al. Oct 2007 A1
20070233237 Krivoruchko Oct 2007 A1
20070233238 Huynh et al. Oct 2007 A1
20070238979 Huynh et al. Oct 2007 A1
20070239254 Marchand et al. Oct 2007 A1
20070239265 Birdsall Oct 2007 A1
20070239266 Birdsall Oct 2007 A1
20070239269 Dolan et al. Oct 2007 A1
20070239273 Allen Oct 2007 A1
20070244544 Birdsall et al. Oct 2007 A1
20070244545 Birdsall et al. Oct 2007 A1
20070244546 Francis Oct 2007 A1
20070244553 Rafiee et al. Oct 2007 A1
20070244554 Rafiee et al. Oct 2007 A1
20070244555 Rafiee et al. Oct 2007 A1
20070244556 Rafiee et al. Oct 2007 A1
20070244557 Rafiee et al. Oct 2007 A1
20070250160 Rafiee Oct 2007 A1
20070255394 Ryan Nov 2007 A1
20070255396 Douk et al. Nov 2007 A1
20070288000 Bonan Dec 2007 A1
20080004688 Spenser et al. Jan 2008 A1
20080004696 Vesely Jan 2008 A1
20080009940 Cribier Jan 2008 A1
20080015671 Bonhoeffer Jan 2008 A1
20080021552 Gabbay Jan 2008 A1
20080048656 Tan Feb 2008 A1
20080065011 Marchand et al. Mar 2008 A1
20080065206 Liddicoat Mar 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080071362 Tuval et al. Mar 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080071366 Tuval et al. Mar 2008 A1
20080071368 Tuval et al. Mar 2008 A1
20080077234 Styrc Mar 2008 A1
20080082165 Wilson et al. Apr 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080133003 Seguin et al. Jun 2008 A1
20080140189 Nguyen et al. Jun 2008 A1
20080147105 Wilson et al. Jun 2008 A1
20080147180 Ghione et al. Jun 2008 A1
20080147181 Ghione et al. Jun 2008 A1
20080147182 Righini et al. Jun 2008 A1
20080154356 Obermiller et al. Jun 2008 A1
20080161910 Revuelta et al. Jul 2008 A1
20080161911 Revuelta et al. Jul 2008 A1
20080183273 Mesana et al. Jul 2008 A1
20080188928 Salahieh et al. Aug 2008 A1
20080215143 Seguin et al. Sep 2008 A1
20080215144 Ryan et al. Sep 2008 A1
20080228254 Ryan Sep 2008 A1
20080228263 Ryan Sep 2008 A1
20080234797 Styrc Sep 2008 A1
20080243246 Ryan et al. Oct 2008 A1
20080255651 Dwork Oct 2008 A1
20080255660 Guyenot et al. Oct 2008 A1
20080255661 Straubinger et al. Oct 2008 A1
20080262593 Ryan et al. Oct 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090012600 Styrc et al. Jan 2009 A1
20090048656 Wen Feb 2009 A1
20090054976 Tuval et al. Feb 2009 A1
20090069886 Suri et al. Mar 2009 A1
20090069887 Righini et al. Mar 2009 A1
20090069889 Suri et al. Mar 2009 A1
20090138079 Tuval et al. May 2009 A1
20090164004 Cohn Jun 2009 A1
20090171447 VonSegesser et al. Jul 2009 A1
20090192585 Bloom et al. Jul 2009 A1
20090192586 Tabor et al. Jul 2009 A1
20090192591 Ryan et al. Jul 2009 A1
20090198316 Laske et al. Aug 2009 A1
20090216310 Straubinger et al. Aug 2009 A1
20090216312 Straubinger et al. Aug 2009 A1
20090216313 Straubinger et al. Aug 2009 A1
20090240264 Tuval et al. Sep 2009 A1
20090240320 Tuval Sep 2009 A1
20090287299 Tabor et al. Nov 2009 A1
20090292350 Eberhardt et al. Nov 2009 A1
20100011564 Millwee et al. Jan 2010 A1
20100018447 Holecek et al. Jan 2010 A1
20100023120 Holecek et al. Jan 2010 A1
20100036484 Hariton et al. Feb 2010 A1
20100094411 Tuval et al. Apr 2010 A1
20100100167 Bortlein et al. Apr 2010 A1
20100131054 Tuval et al. May 2010 A1
20100137979 Tuval et al. Jun 2010 A1
20110276128 Cao et al. Nov 2011 A1
20120203335 Vesely et al. Aug 2012 A1
Foreign Referenced Citations (66)
Number Date Country
2007-100074433 Aug 2007 CN
195 32 846 Mar 1997 DE
195 46 692 Jun 1997 DE
195 46 692 Jun 1997 DE
198 57 887 Jul 2000 DE
199 07 646 Aug 2000 DE
100 48 814 Sep 2000 DE
10 49 815 Apr 2002 DE
100 49 812 Apr 2002 DE
100 49 813 Apr 2002 DE
0103546 Mar 1984 EP
0597967 Dec 1994 EP
0850607 Jul 1998 EP
1057459 Jun 2000 EP
1057460 Jun 2000 EP
1088529 Apr 2001 EP
1255510 Nov 2002 EP
0937439 Sep 2003 EP
1340473 Sep 2003 EP
0819013 Jun 2004 EP
2788217 Dec 1999 FR
2056023 Mar 1981 GB
2433700 Dec 2007 GB
9529640 Nov 1995 WO
9814137 Apr 1998 WO
9829057 Jul 1998 WO
9933414 Jul 1999 WO
0041652 Jul 2000 WO
0044313 Aug 2000 WO
0047136 Aug 2000 WO
0047139 Aug 2000 WO
0135870 May 2001 WO
0149213 Jul 2001 WO
0154625 Aug 2001 WO
0162189 Aug 2001 WO
0164137 Sep 2001 WO
0176510 Oct 2001 WO
0222054 Mar 2002 WO
0236048 May 2002 WO
0241789 May 2002 WO
0243620 Jun 2002 WO
0247575 Jun 2002 WO
0249540 Jun 2002 WO
03003943 Jan 2003 WO
03003949 Jan 2003 WO
03011195 Feb 2003 WO
03030776 Apr 2003 WO
2004019811 Mar 2004 WO
2004019825 Mar 2004 WO
2004023980 Mar 2004 WO
2004041126 May 2004 WO
2004058106 Jul 2004 WO
2004089250 Oct 2004 WO
2005004753 Jan 2005 WO
2005027790 Mar 2005 WO
2005046528 May 2005 WO
2008047354 Apr 2008 WO
2008079962 Jul 2008 WO
2008100599 Aug 2008 WO
2008150529 Dec 2008 WO
2009002548 Dec 2008 WO
2009029199 Mar 2009 WO
2009042196 Apr 2009 WO
2009045338 Apr 2009 WO
2009061389 May 2009 WO
2009091509 Jul 2009 WO
Non-Patent Literature Citations (37)
Entry
U.S. Appl. No. 12/476,702, filed Jun. 2, 2009.
U.S. Appl. No. 12/711,289, filed Feb. 24, 2010.
Andersen, H.R. et al, “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.” Euro. Heart J. (1992) 13:704-708.
Babaliaros, et al., “State of the Art Percutaneous Intervention for the Treatment of Valvular Heart Disease: A Review of the Current Technologies and Ongoing Research in the Field of Percutaneous Heart Valve Replacement and Repair,” Cardiology 2007; 107:87-96.
Bailey, “Percutaneous Expandable Prosthetic Valves,” In: Topol EJ, ed. Textbook of Interventional Cardiology. vol. II. Second edition. WB Saunders, Philadelphia, 1994:1268-1276.
Block, et al., “Percutaneous Approaches to Valvular Heart Disease,” Current Cardiology Reports, vol. 7 (2005) pp. 108-113.
Bonhoeffer, et al, “Percutaneous Replacement of Pulmonary Valve in a Right-Ventricle to Pulmonary-Artery Prosthetic Conduit with Valve Dysfunction,” Lancet (England), Oct. 21, 2000, pp. 1403-1405.
Bonhoeffer, et al, “Transcatheter Implantation of a Bovine Valve in Pulmonary Position: A Lamb Study,” Circulation (United States), Aug. 15, 2000, pp. 813-816.
Boudjemline, et al, “Images in Cardiovascular Medicine. Percutaneous Aortic Valve Replacement in Animals,” Circulation (United States), Mar. 16, 2004, 109, p. e161.
Boudjemline, et al, “Percutaneous Aortic Valve Replacement: Will We Get There?” Heart (British Cardiac Society) (England), Dec. 2001, pp. 705-706.
Boudjemline, et al, “Percutaneous Implantation of a Biological Valve in the Aorta to Treat Aortic Valve Insufficiency—A Sheep Study,” Medical Science Monitor—International Medical Journal of Experimental and Clinical Research (Poland), Apr. 2002, pp. BR113-BR116.
Boudjemline, et al, “Percutaneous Implantation of a Biological Valve in Aortic Position: Preliminary Results in a Sheep Study,” European Heart Journal 22, Sep. 2001, p. 630.
Boudjemline, et al, “Percutaneous Pulmonary Valve Replacement in a Large Right Ventricular Outflow Tract: An Experimental Study,” Journal of the American College of Cardiology (United States), Mar. 17, 2004, pp. 1082-1087.
Boudjemline, et al, “Percutaneous Valve Insertion: A New Approach,” Journal of Thoracic and Cardiovascular Surgery (United States), Mar. 2003, pp. 741-742.
Boudjemline, et al, “Steps Toward Percutaneous Aortic Valve Replacement,” Circulation (United States), Feb. 12, 2002, pp. 775-758.
Boudjemline, et al, “The Percutaneous Implantable Heart Valve,” Progress in Pediatric Cardiology (Ireland), 2001, pp. 89-93.
Coats, et al, “The Potential Impact of Percutaneous Pulmonary Valve Stent Implantation on Right Ventricular Outflow Tract Re-Intervention,” European Journal of Cardio-Thoracic Surgery (England), Apr. 2005, pp. 536-543.
Cribier, A. et al, “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description,” Circulation (2002) 3006-3008.
Davidson et al., “Percutaneous therapies for valvular heart disease,” Cardiovascular Pathology 15 (2006) 123-129.
Hanzel, et al., “Complications of percutaneous aortic valve replacement: experience with the Criber-Edwards™ percutaneous heart valve,” EuroIntervention Supplements (2006), 1 (Supplement A) A3-A8.
Khambadkone, “Nonsurgical Pulmonary Valve Replacement: Why, When, and How?” Catheterization and Cardiovascular Interventions—Official Journal of the Society for Cardiac Angiography & Interventions (United States), Jul. 2004, pp. 401-408.
Khambadkone, et al, “Percutaneous Implantation of Pulmonary Valves,” Expert Review of Cardiovascular Therapy (England), Nov. 2003, pp. 541-548.
Khambadkone, et al, “Percutaneous Pulmonary Valve Implantation: Early and Medium Term Results,” Circulation 108 (17 Supplement), Oct. 28, 2003, p. IV-375.
Lutter, et al, “Percutaneous Aortic Valve Replacement: An Experimental Study. 1. Studies on Implantation,” The Journal of Thoracic and Cardiovascular Surgery, Apr. 2002, pp. 768-776.
Lutter, et al, “Percutaneous Valve Replacement: Current State and Future Prospects,” Annals of Thoracic Surgery (Netherlands), Dec. 2004, pp. 2199-2206.
Medtech Insight, “New Frontiers in Heart Valve Disease,” vol. 7, No. 8 (2005).
Palacios, “Percutaneous Valve Replacement and Repair, Fiction or Reality?” Journal of American College of Cardiology, vol. 44, No. 8 (2004) pp. 1662-1663.
Pasupati et al., “Transcatheter Aortic Valve Implantation Complicated by Acute Structural Valve Failure Requiring Immediate Valve in Valve Implantation,” Heart, Lung and Circulation 2010; doi:10.1016/j.hlc.2010.05.006.
Pelton et al., “Medical Uses of Nitinol,” Materials Science Forum vols. 327-328, pp. 63-70 (2000).
Ruiz, “Transcathether Aortic Valve Implantation and Mitral Valve Repair: State of the Art,” Pediatric Cardiology, vol. 26, No. 3 (2005).
Webb, et al., “Percutaneous Aortic Valve Implantation Retrograde from the Femoral Artery,” Circulation (2006), 113;842-850.
Expert report of Dr. Nigel Buller, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (83 pages).
Expert report of Dr. Nigel Buller, non-confidential annex—infringement, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (12 pages).
Expert report of Dr. Rodolfo Quijano, dated Jan. 9, 2009, Edwards' LifeSciences v. Cook Biotech Incorporated, United Kingdom action for invalidity, Claim No. HC 08CO0934 (18 pages).
First Expert report of Prof. David Williams, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (41 pages).
Pavcnik et al., “Aortic and venous valve for percutaneous insertion,” Min. Invas. Ther. & Allied Techol. 2000, vol. 9, pp. 287-292.
First Expert report of Dr. Nigel Person Buller (30 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.
Related Publications (1)
Number Date Country
20100023120 A1 Jan 2010 US
Provisional Applications (1)
Number Date Country
61125203 Apr 2008 US